US' Custom mRNA Vaccine Scores Phase 3 Win Against Deadly Skin Cancer
The trial enrolled 1,137 patients and met its primary endpoint, with the vaccine encoding up to 34 neoantigens alongside pembrolizumab.
- The Phase III INTerpath-001 trial met its primary endpoint, demonstrating improved recurrence-free survival in 1,137 patients with high-risk melanoma. Moderna and Merck's personalized vaccine combined with PD-1 immunotherapy succeeded where Keytruda alone did not.
- Scientists design this personalized vaccine by identifying DNA mutations within each patient's tumor. Each treatment encodes up to 34 neoantigens, and RNA is injected under the skin every 3 weeks alongside immunotherapy to instruct immune cells to attack remaining cancer cells.
- Prof Marco Gerlinger, a Consultant Medical Oncologist at Barts Cancer Institute, called it the first Phase III study showing protection against melanoma recurrences. Moderna CEO Stephane Bancel described the findings as a "pivotal moment" in cancer research.
- Nearly 50 cancer centers across the United Kingdom, including those in the NHS Cancer Vaccine Launch Pad, contributed to this national effort. Cancer Research expert Dr Talisia Quallo said the research "shows promise" while emphasizing the need for continued funding.
- Dr Lennard Lee, a Consultant Medical Oncologist at the University of Oxford, said the study provides "proof of principle that personalised cancer vaccines work." Moderna and Merck are testing similar personalized vaccines for lung, bladder, and kidney cancers.
39 Articles
39 Articles
Vaccine Breakthrough Prevents Cancer Returning In Trial
A personalised cancer vaccine has delivered a potentially major breakthrough. Helping keep high-risk melanoma from returning when combined with an existing immunotherapy drug.Developed by Moderna and Merck/MSD, the vaccine, called Intismeran, was tested alongside Keytruda. It was tested in more than 1,000 patients after surgery.The early results are striking: compared with Keytruda alone, the combination significantly extended the time patients …
The personalized vaccine extended the period during which patients were cancer-free, but it is not clear for how long.
Morning Checkup | Cancer vaccine reduces recurrence risk and death
A study involving over 1,100 patients found that combining Moderna and Merck's mRNA vaccine, intismeran, with the immunotherapy Keytruda reduced the risk of melanoma recurrence or death by 49% over five years.
US' custom mRNA vaccine scores Phase 3 win against deadly skin cancer
US pharmaceutical and biotechnology firm, Moderna, gained fame in 2020 after developing one of the first effective mRNA COVID-19 vaccines. Now, along with Merck, it has unveiled a personalized mRNA vaccine that shows massive promise in preventing melanoma from returning. Called intismeran autogene (or mRNA-4157/V940), the messenger RNA (mRNA)-based individualized neoantigen therapy (INT) comes encapsulated in solid lipid nanoparticles. It contai…
MRNA technology trains the immune system from the genetic profile of the tumor to prevent damage to healthy cells caused by traditional chemotherapy
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
